Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
M Bronstein, University of São Paulo Medical School, Brazil
The efficacy and safety of pasireotide LAR (40 mg), a multi-receptor targeted somatostatin analogue with high affinity for somatostatin receptor subtypes 1, 2, 3 and 5, will be assessed in 359 patients from 116 sites in 27 countries with active acromegaly versus octreotide LAR (20 mg). Patients will be dosed once every 28 days for 12 months, with titrations at 3 and 7 months as required. Results from this large, randomised, Phase III study will help determine the efficacy and safety of pasireotide LAR in the treatment of patients with active acromegaly.
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.